Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL

Rhea-AI Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) presented promising preclinical data at the AACR Annual Meeting 2023, showcasing the efficacy of its dual-targeting INTASYL therapy targeting PD-1 and CTLA-4 in mouse models of colon cancer. This innovative approach demonstrated enhanced anti-tumor activity compared to single-target therapies while maintaining a favorable safety profile. Dr. Mary Spellman emphasized the potential of intratumoral administration to mitigate the high incidence of immune-related adverse events associated with systemic treatments. This breakthrough could represent a significant advancement in immuno-oncology, reflecting Phio's commitment to developing effective cancer therapies.

Positive

• Demonstrated enhanced anti-tumor efficacy in mouse models from dual-targeting formulation compared to single-target therapies.
• Well-tolerated dual-targeting therapy suggests potential for improved safety profile.
• Innovative approach may reduce systemic immune-related adverse events associated with existing therapies.

Negative

• None.

- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 -

MARLBOROUGH, Mass., April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Intratumoral administration of the PD-1/CTLA-4 INTASYL improved tumor control compared to either single targeting formulation, at an identical total dose. The dual-targeting formulation was well tolerated.

"The synergistic effects of dual inhibition of PD-1 and CTLA-4 in enhancing tumor response are clinically recognized, however, a high rate of immune-related adverse events limits the utility of systemic use of this combination of products," said Dr. Mary Spellman, Phio's Acting Chief Medical Officer. "Intratumoral administration of dual-targeting PD-1/CTLA-4 INTASYL may provide an effective treatment option, with an improved safety profile."

Presentation Details:

Poster Title:	INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4 provides synergistic antitumor efficacy in the treatment of murine colon cancer in vivo
Session Date and Time:	Tuesday, April 18, 2023 from 1:30 PM - 5:00 PM EST

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

For additional information, visit the Company's website, www.phiopharma.com.  

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward looking statements include statements regarding dual-targeting PD-1/CTLA-4 INTASYL's potential to provide an effective treatment option with improved safety profiles. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, military conflict between Ukraine and Russia, inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com 

Investor Contact
Ashley R. Robinson 
LifeSci Advisors
arr@lifesciadvisors.com 

View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-presents-preclinical-data-demonstrating-synergy-enhanced-in-vivo-anti-tumor-efficacy-of-pd-1ctla-4-dual-targeting-intasyl-301799637.html

SOURCE Phio Pharmaceuticals Corp.

FAQ

What are the results of Phio Pharmaceuticals' dual-targeting INTASYL therapy?

Phio Pharmaceuticals presented data showing that its dual-targeting INTASYL therapy targeting PD-1 and CTLA-4 enhanced anti-tumor efficacy in mouse models compared to single-target therapies.

When was the data from Phio Pharmaceuticals presented?

The data was presented on April 18, 2023, at the AACR Annual Meeting.

What is the significance of the dual-targeting mechanism in INTASYL therapy?

The dual-targeting mechanism is significant as it provides synergistic anti-tumor effects while potentially reducing immune-related adverse events associated with systemic treatments.

What is the potential impact of Phio Pharmaceuticals' therapy on cancer treatment?

This therapy could enhance the treatment options available for cancer patients, offering a more effective and safer method to utilize PD-1 and CTLA-4 inhibition.